Johnson And Johnson

J&J Q3 earnings beat expectations, make progress on talc liabilities

Adjusted profit was $2.42 a share, surpassing Wall Street's average estimate of $2.19. Pharmaceutical revenue rose almost 5 per cent, exceeding expectations by more than $400 million

J&J raises baby powder settlement offer to more than $8.2 billion

J&J recently garnered support from more than 75 per cent of baby powder claimants for an out-of-court deal that includes claims that the talc-based version caused ovarian and other gynecological cance

Johnson & Johnson to pay additional $1.1 bn to resolve talc settlement

The increase would boost the size of the settlement to more than $9 billion paid over 25 years

US court jury directs J&J to pay $260 million to baby powder user

J&J now faces more than 61,000 suits blaming talc for different types of cancers. Many of the cases have been consolidated before a federal judge in New Jersey

WHO says wider warning about contaminated J&J cough syrup 'likely'

Nigeria's regulator recalled a batch of Benylin syrup last Wednesday, having found a high level of diethylene glycol in the product during routine testing

J&J Q1 results: Profit beats expectations on cancer drugs strength

Sales of its blockbuster psoriasis drug Stelara were flat at $2.45 billion in the first quarter, while sales of Darzalex jumped about 19% to $2.69 billion

J&J can contest evidence linking its talc to ovarian cancer, says US judge

Shipp took over the case in February 2023, after the retirement of former Chief District Judge Freda Wolfson, who had overseen the litigation since 2016

Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug

Biocon said that the U.S. FDA has accepted the Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway

J&J to pay $700 mn to settle talc investigation by more than 40 US states

Shares of J&J fell slightly as trading began Monday morning in New York, but closed with a 0.25 per cent gain at $161.53. The stock fell 11 per cent last year

J&J, Lupin cut prices for tuberculosis drug in lower-income countries

(Reuters) - Johnson & Johnson and Indian drugmaker Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, a global anti-tuberculosis group said on Wednesday.

J&J can't use bankruptcy to settle 100,000 baby powder cancer claims: Judge

J&J shares dropped as much as 3.4% in post-market trading following the ruling. The company vowed to appeal Judge Kaplan's ruling

J&J sues US govt to block Medicare drug price negotiation plans: Report

Pharmaceutical industry says the drug price negotiation program that is part of President Joe Biden's IRA will curtail profits and compel them to pull back on developing groundbreaking new treatment

J&J wins pause of baby powder trials, must face new suits, says judge

US Bankruptcy Judge Michael Kaplan said Thursday the company won't have to go to trial over any talc lawsuits for at least 60 days, but new lawsuits can be filed

J&J May Need to Defend Baby Powder Cancer Suits After 19-Month Pause

The company says it has a deal backed by as many as 80,000 claimants, which should be enough to meet a key legal threshold to push a settlement worth $8.9 billion through bankruptcy

Johnson&Johnson sales in US rise 10%, health care giant raises dividend

Johnson & Johnson beat first-quarter expectations, as growth in the health care giant's home market helped counter another revenue hit overseas from a strong dollar. The health care giant booked a USD 68 million loss on a one-time charge in the quarter, and revenue grew more than 5 per cent to USD 24.75 billion, which was better than anticipated. Adjusted earnings totalled USD 2.68 per share, topping Wall Street projections for per-share earnings of USD 2.50, according to a survey by FactSet. Johnson & Johnson sells prescription drugs and medical devices. It is splitting off its consumer health business, which includes well-known products like BandAids. The company expects to complete the separation this year. Sales in the US grew nearly 10 per cent to USD 12.52 billion in the quarter, while international sales climbed nearly 2 per cent. A strong US dollar can affect sales for companies that do a lot of international business. They have to convert those sales into dollars when

Wall St up as Goldman results keep optimism alive, rising yields cap gains

The benchmark 10-year Treasury note reversed early declines to rise for the fourth straight day, while big technology and growth names like Apple Inc, Amazon.com and Nvidia Corp cut back gains

Q3 results: Johnson & Johnson beats estimates on demand for cancer drug

The company said it expects some impact of inflation to ease next year but higher costs of inventory manufactured in 2022 could weigh on 2023 profit

Maharashtra FDA axe Johnson & Johnson's baby powder manufacturing license

Maharashtra's Food and Drugs Administration (FDA) on Friday cancelled the baby powder manufacturing licence of Johnson & Johnson Pvt Ltd "in the interest of public health at large". In a release, the state government agency said the company's product, Johnson's Baby Powder, may affect the skin of newborn babies. Samples of the powder for babies did not conform to standard pH value during a laboratory test, the regulator said. The release said the action was taken after Kolkata-based Central Drugs Laboratory's conclusive report that concludes "the sample does not conform to IS 5339:2004 with respect to the test for pH. According to the release, FDA had drawn samples of Johnson's Baby Powder from Pune and Nashik for quality check purposes. The government analyst had declared the samples as "not of the standard quality" as they do not comply with IS 5339:2004 specification for skin powder for infants in the test pH, it said. Thereafter, FDA issued a show-cause notice to ...

Explained: What is the controversy around J&J's talc-based baby powder?

Johnson and Johnson (J&J) has been facing several thousand lawsuits from women who claim that they developed ovarian cancer after using the product

Johnson and Johnson: Why talc-based powder will stop their sales in 2023?

After 38,000 serious allegations, Johnson and Johnson's talc-based baby powder will stop international sales from 2023. The product has already been discontinued in the US and Canada